[Press Release] InnoCellular Joins Forces with EVANTICA to Pioneer Anti-Cancer Therapy Technology using MSC-derived Extracellular Vesicles

InnoCellular Joins Forces with EVANTICA to Pioneer  Anti-Cancer Therapy Technology using MSC-derived Extracellular Vesicles

• InnoCellular and EVANTICA focus on the expansion of Mesenchymal Stem Cells (MSCs) for EV harvest in bioreactors using InnoCellular’s proprietary media.
• In collaboration with EVANTICA, InnoCellular aims to co-develop a new media recipe specifically tailored for MSC-EV harvest.

Singapore, July 9 2024 —InnoCellular Tech Pte Ltd (“InnoCellular”) is excited to announce its role as an industrial partner for the EVANTICA (Engineered Extracellular Vesicles for Anti-Cancer Therapy) program, spearheaded by Assistant Professor Minh LE from the National University of Singapore and Professor Jonathan LOH from the Agency for Science, Technology and Research, Institute of Molecular and Cell Biology (A*STAR IMCB), advised by Professor Harvey LODISH from the Whitehead Institute from the Massachusetts Institute of Technology, with the goal of developing a cutting-edge platform technology for anti-cancer therapy.

The EVANTICA research team seeks to create an innovative technology that leverages the high specificity and efficacy of engineered extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs). This approach promises to revolutionize cancer treatment by offering a targeted and potent therapeutic solution.

In this collaboration, InnoCellular and IMCB will provide their expertise in MSC expansion using proprietary media recipe from InnoCellular. This media recipe has shown exceptional results, achieving robust MSC expansion in bioreactors with yields at least double those of conventional media. Additionally, InnoCellular will work closely with EVANTICA to co-develop a new media recipe specifically tailored for MSC-EV harvest.

InnoCellular made a successful debut at the EVANTICA symposium on July 4, 2024, showcasing how the advanced technology can support the EVANTICA program. The presentation highlighted the potential of InnoCellular’s proprietary media recipe to enhance MSC expansion in 3D cell manufacturing for EV harvest, emphasizing the company’s commitment to advancing innovative technologies that have the potential to transform cancer therapy.

The collaboration between InnoCellular and EVANTICA marks a significant advancement in the development of next-generation therapy. By combining InnoCellular’s advanced media solutions with EVANTICA’s pioneering research, this partnership aspires to deliver the next generation of highly effective and targeted anti-cancer therapies.

For more information about InnoCellular and its initiatives in cell therapy innovation, please visit www.innocellular.com.

About InnoCellular

At the forefront of advancing therapeutic technologies, InnoCellular Tech Pte Ltd specializes in developing efficient and cost-effective cell culture media for stem cells and specialized cell applications. Known for our expertise, we excel in formulating high-performance, consistent, and top-quality media for next-generation therapies. Our services include a diverse range of options, from basal to specialty formulations, designed for research-only or cGMP purposes, all tailored with exceptional flexibility to meet your specific experimental or clinical needs.

About EVANTICA

EVANTICA (Engineered Extracellular Vesicles for Anti-Cancer Therapy), led by Assistant Professor Minh LE from the National University of Singapore and Professor Jonathan LOH from the Agency for Science, Technology and Research, Institute of Molecular and Cell Biology (A*STAR IMCB), is supported by a team of experienced scientists, clinicians, entrepreneurs, and industry partners with expertise in drug delivery, stem cell engineering, biomaterial engineering, cancer biology, pharmacology, and clinical trials. The program aims to develop an innovative platform technology for anti-cancer therapy, focusing on high specificity and efficacy using engineered extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs).

For media queries, please contact:

Tanny KEA
Chief Operating Officer, InnoCellular Tech Pte Ltd
[email protected]

SAM Tsz Wing, Sara Ph.D
Manager (Strategic Planning and Communications), InnoCellular Tech Pte Ltd
[email protected]
Block 79 Ayer Rajah Crescent, #05-03, Singapore 139955

For general queries, please contact:

[email protected]

Click her to download full pdf version of Press Release:  PR04 20240709 InnoCellular Joins Forces with EVANTICA to Pioneer  Anti-Cancer Therapy Technology using MSC-derived Extracellular Vesicles